Anxiety and Parkinson's disease

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 8, Issue 4, 1996, Pages 383-392

  Richard, Irene Hegeman ^a   Schiffer, Randolph B ^a   Kurlan, Roger ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BROMOCRIPTINE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; CLINICAL FEATURE; DEMENTIA; DEPRESSION; DRUG CONTRAINDICATION; HUMAN; MAJOR CLINICAL STUDY; NEUROBIOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0029822513     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.8.4.383     Document Type: Review

References (81)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised (1987), and 4th edition (1994). Washington, DC, American Psychiatric Association
2. Rubin AJ, Kurlan R, Schiffer R, et al: Atypical depression and Parkinson's disease (abstract). Ann Neurol 1986; 20:150
3. Stein M, Henser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147:217-220
4. Vázquez A, Jiménez-Jiménez FJ, Garcia-Ruiz P, et al: "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand 1993; 87:14-18
5. Schiffer RB, Kurlan R, Rubin A, et al: Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988; 145:1020-1022
6. Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34:465-470
7. Menza MA, Mark MH: Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1994; 6:165-169
8. Gotham A-M, Brown RG, Marsden CD: Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:381-389
9. Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 1992; 148:274
10. Henderson R, Kurlan R, Kersun JM, et al: Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:257-264
11. Siemers ER, Shekhar A, Quaid K, et al: Anxiety and motor performance in Parkinson's disease. Mov Disord 1993; 8:501-506
12. Rondot P, deRecondo J, Colgnet A, et al: Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 1984; 40
13. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149:443-454
14. Nissenbaum H, Quinn NP, Brown RG, et al: Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med 1987; 17:899-904
15. Seligman MEP: Chronic fear produced by unpredictable shock. Journal of Comparative and Physiological Psychology 1968; 66:402-411
16. Riley DE, Lang AE: The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43:1459-1464
17. Marsden CD, Parkes JD: "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296
18. Menza MA, Sage J, Marshall E, et al: Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990; 5:148-151
19. Brown RG, Marsden CD, Quinn N, et al: Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47:454-465
20. Cantello R, Gilli M, Riccio A, et al: Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry 1986; 49:1182-1190
21. Routh LC, Black JL, Ahlskog JE: Parkinson's disease complicated by anxiety. Mayo Clin Proc 1987; 62:733-735
22. Kurlan R, Lichter D, Schiffer RB: Panic/anxiety in Parkinson's disease: yohimbine challenge (abstract). Neurology 1989; 39(suppl 1):421
23. Flint AJ: Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994; 151:640-649
24. Raj BA, Corvea MH, Dagon EM: The clinical characteristics of panic disorder in the elderly: a retrospective study. J Clin Psychiatry 1993; 54:150-155
25. Lydiard RB: Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991; 52(suppl 6):48-54
26. Fleminger S: Left-sided Parkinson's disease is associated with greater anxiety and depression. Psychol Med 1991; 21:629-638
27. Wands K, Merskey H, Hachinski VC, et al: A questionnaire investigation of anxiety and depression in early dementia. J Am Geriatr Soc 1990; 38:535-538
28. Iruela LM, Ibañez-Rojo V, Inmaculada P, et al: Anxiety disorders and Parkinson's disease (letter). Am J Psychiatry 1992; 149:719-720
29. Cash R, Dennis T, L'Heureux R, et al: Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987; 37:42-46
30. Lauterbach EC: The locus ceruleus and anxiety disorders in demented and nondemented familial parkinsonism (letter). Am J Psychiatry 1993; 150:994
31. Nutt D, Lawson C: Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry 1992; 160:165-178
32. Heninger GR, Charney DS: Monoamine receptor systems and anxiety disorders. Psychiatr Clin North Am 1988; 11:309-326
33. Charney DS, Heninger GR, Brief A: Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41:751-763
34. Charney DS, Woods SW, Goodman WK, et al: Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144:1030-1036
35. Nutt DJ: Altered alpha-2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry 1989; 46:165-169
36. Uhde T, Stein MB, Vittone BJ, et al: Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989; 46:170-177
37. Charney DS, Heninger GR: Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43:1042-1054
38. Agid Y, Cervera P, Hirsch E, et al : Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 1989; 4(suppl 1):5126-5144
39. Weiner WJ, Lang AE: Movement Disorders: A Comprehensive Survey. Mount Kisco, NY, Futura, 1989
40. Patt S, Gerhard L: A study of human locus ceruleus in normal brains and in Parkinson's disease. Neuropathol Appl Neurobiol 1993; 19:519-523
41. German DC, Manaye KF, White CL III, et al: Disease-specific patterns of locus ceruleus cell loss. Ann Neurol 1992; 32:667-676
42. Chan-Palay V: Depression and dementia in Parkinson's disease: catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 1993; 60:438-446
43. Zweig RM, Cardillo JE, Cohen M, et al: The locus ceruleus and dementia in Parkinson's disease. Neurology 1993; 43:986-991
44. Cash R, Ruberg M, Raisman R, et al: Adrenergic receptors in Parkinson's disease. Brain Res 1984; 322:269-275
45. Villeneuve A, Berlan M, Lafontan M, et al: Platelet alpha-2-adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment. Eur J Clin Invest 1985; 15:403-407
46. Montastruc J-L, Villeneuve A, Berlan M, et al: Study of platelet alpha-2-adrenoceptors in Parkinson's disease. Adv Neurol 1986; 45:253-258
47. Berlan M, Rascol O, Belin J, et al: Alpha-2 adrenergic sensitivity in Parkinson's disease. Clin Neuropharmacol 1989; 12:138-144
48. Insel TR, Zohar J, Benkelfat C, et al : Serotonin in obsessions, compulsions, and the control of aggressive impulses. Ann NY Acad Sci 1990; 600:574-585
49. Miner CM, Davidson JR: Biological characterization of social phobia (review). Eur Arch Psychiatry Clin Neurosci 1995; 244:304-308
50. Charney DS, Woods SW, Krystal JH, et al: Serotonin function and human anxiety disorders. Ann NY Acad Sci 1990; 600:558-572
51. Halliday GM, Blumbergs PC, Cotton RG, et al: Loss of brainstem serotonin and substance P-containing neurons in Parkinson's disease. Brain Res 1990; 510:104-107
52. Jellinger K: The pathology of parkinsonism, in Movement Disorders, vol 2, edited by Marsden CD, Fahn S (International Medical Reviews, Neurology; vol 7). London, Butterworth, 1987, pp 124-165
53. Agid Y, Javoy-Agid F, Ruberg M: Biochemistry of neurotransmitters in Parkinson's disease, in Movement Disorders, vol 2, edited by Marsden CD, Fahn S (International Medical Reviews,Neurology; vol 7). London, Buttenvorth, 1987, pp 166-230
54. Raisman R, Cash R, Agid Y: Parkinson's disease: decreased density 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986; 36:556-560
55. D'Amato RJ, Zweig RM, Whitehouse PJ, et al: Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987; 22:229-236
56. Potts NLS, Davidson JRT: Social phobia: biological aspects and pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:635-646
57. Pitchot W, Ansseau M, Gonzalez Moreno A, et al: Dopaminergic function in panic disorder: comparison with major and minor depression. Biol Psychiatry 1992; 32:1004-1011
58. Argyl N: Panic attacks in chronic schizophrenia. Br J Psychiatry 1990; 157:430-433
59. McDougle CJ, Goodman WK, Price LH: Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder (literature review). J Clin Psychiatry 1994; 55(suppl):24-31
60. Marazziti D, Hollander E, Lensi P, et al: Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 1992; 42:41-51
61. Tomer R, Levin BE, Weiner WJ: Obsessive-compulsive symptoms and motor asymmetries in Parkinson's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1993; 6:26-30
62. Cedarbaum JM, Aghajanian GK: Catecholamine receptors on locus ceruleus neurons: pharmacological characterization. Eur J Pharmacol 1977; 44:375-385
63. Owens MJ, Nemeroff CB: The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Foundation Symposium 1993; 172:296-308
64. Fontaine R, Breton G, Dery R, et al: Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry 1990; 27:304-310
65. Reiman EM, Raichle ME, Butler FK, et al: A focal brain abnormality in panic disorder: a severe form of anxiety. Nature 1984; 310:683-685
66. Faulstich ME, Sullivan DC: Positron emission tomography in neuropsychiatry. Invest Radiol 1991; 26:184-194
67. Wu JC, Buchsbaum MS, Hershey TG, et al: PET in generalized anxiety disorder. Biol Psychiatry 1991; 29:1181-1199
68. Davidson JRT, Krishnan KRR, Charles HC, et al: Magnetic resonance spectroscopy in social phobia: preliminary findings. J Clin Psychiatry 1993; 54(suppl 12):19-25
69. Potts NLS, Davidson JRT, Krishnan KRR, et al: Magnetic resonance imaging in social phobia. Psychiatry Res 1994; 52:35-42
70. Hollander E, Cohen L, Richards M, et al: A pilot study of the neuropsychology of obsessive-compulsive disorder and Parkinson's disease: basal ganglia disorders. J Neuropsychiatry Clin Neurosci 1993; 5:104-107
71. Saint-Cyr JA, Taylor AE, Nicholson K: Behavior and the basal ganglia (literature review). Adv Neurol 1995; 65:1-28
72. Ludwig CL, Weinberger DR, Bruno G, et al: Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9:373-378
73. Bonifati V, Fabrizio E, Cipriani R, et al: Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994; 17:73-82
74. Mann JJ, Aarons SF, Wilner PJ, et al: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch Gen Psychiatry 1989; 46:45-50
75. Steur ENHJ: Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43:211-213
76. Chouinard G, Sultan S: A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacology 1992; 7:63-66
77. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, et al: Parkinsonism exacerbated by paroxetine. Neurology 1994; 44:2406
78. Caley CF, Friedman JH: Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992; 53:278-82
79. Montastruc J-L, Fabre N, Blin O, et al: Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 1995; 10:355-357
80. Stoudemire A, Moran MG: Psychopharmacologic treatment of anxiety in the medically ill elderly patient: special considerations. J Clin Psychiatry 1993; 54(suppl 5):27-33
81. Salzman C: Anxiety in the elderly: treatment strategies. J Clin Psychiatry 1990; 51(suppl 10):18-21